These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 21854080)

  • 1. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.
    Scotland G; Waugh N; Royle P; McNamee P; Henderson R; Hollick R
    Pharmacoeconomics; 2011 Nov; 29(11):951-61. PubMed ID: 21854080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.
    Yang H; Craig D; Epstein D; Bojke L; Light K; Bruce IN; Sculpher M; Woolacott N
    Pharmacoeconomics; 2012 Apr; 30(4):257-70. PubMed ID: 22283690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab for the prevention of osteoporotic fractures in postmenopausal women.
    Waugh N; Royle P; Scotland G; Henderson R; Hollick R; McNamee P
    Health Technol Assess; 2011 May; 15 Suppl 1():51-9. PubMed ID: 21609653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
    Ström O; Jönsson B; Kanis JA
    Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
    Stevenson M; Davis S; Lloyd-Jones M; Beverley C
    Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
    Hiligsmann M; Reginster JY
    Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.
    Kilonzo M; Hislop J; Elders A; Fraser C; Bissett D; McClinton S; Mowatt G; Vale L
    Pharmacoeconomics; 2013 Jan; 31(1):15-24. PubMed ID: 23329590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.
    Rodgers M; Griffin S; Paulden M; Slack R; Duffy S; Ingram JR; Woolacott N; Sculpher M
    Pharmacoeconomics; 2010; 28(5):351-62. PubMed ID: 20131924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China.
    You R; Mori T; Ke L; Wan Y; Zhang Y; Luo F; Feng D; Yu G; Liu J
    Menopause; 2021 Dec; 29(2):210-218. PubMed ID: 34930866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.
    Boyers D; Jia X; Jenkinson D; Mowatt G
    Pharmacoeconomics; 2012 Jun; 30(6):483-95. PubMed ID: 22480381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.
    McKenna C; Maund E; Sarowar M; Fox D; Stevenson M; Pepper C; Woolacott N; Palmer S
    Pharmacoeconomics; 2012 Jan; 30(1):35-46. PubMed ID: 22136303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan.
    Mori T; Crandall CJ; Fujii T; Ganz DA
    Arch Osteoporos; 2021 Jul; 16(1):113. PubMed ID: 34264429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
    Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
    Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis.
    Jiang Y; Jiang S; Li L; Shi S; Li M; Si L
    Appl Health Econ Health Policy; 2023 May; 21(3):489-499. PubMed ID: 36626041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Fayter D; Wolff R; Armstrong N; Stirk L; Worthy G; Albuquerque de Almeida F; Kleijnen J; Al MJ
    Pharmacoeconomics; 2018 Feb; 36(2):145-159. PubMed ID: 29086363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.